Orladeyo denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for orladeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Orladeyo as Experimental

Aetna occasionally applies an "experimental or investigational" denial to Orladeyo (berotralstat) when internal clinical policy reviewers determine that the evidence base does not yet meet the plan's threshold for established efficacy, or when the requested use falls outside the labeled indication. This type of denial is serious but also one of the most frequently overturned categories on appeal, particularly for an FDA-approved drug being prescribed for its approved indication.

## Why This Denial Is Appealable

Orladeyo received full FDA approval for its indicated use in hereditary angioedema (HAE) in adults and adolescents. An FDA-approved drug used for its approved indication is, by definition, not investigational from a regulatory standpoint. If Aetna's denial rests on an experimental classification for an on-label use, the appeal has a strong foundation. Your prescriber should directly address the specific language in Aetna's clinical policy that was cited, and rebut it with reference to the FDA-approved prescribing information and the relevant HAE professional society guidelines.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. For pre-service denials, Aetna must respond within 30 days; for urgent/concurrent care, timelines are shorter.
• External review (ACA §2719): Experimental/investigational denials are explicitly eligible for independent external review under federal law. You may request external review after exhausting internal appeals or after Aetna exceeds its decision deadline. The external reviewer's decision binds the plan. The standard window is 4 months from final internal denial.
• Expedited review: Available if delay would seriously jeopardize your health — request simultaneously with your expedited internal appeal.

## Documentation to Gather

1. Diagnosis confirmation — specialist notes, laboratory or genetic confirmation of HAE, and documented attack history (frequency, severity, hospitalizations). 2. FDA approval reference — include or cite the FDA-approved prescribing information (label) for Orladeyo, confirming the indication matches your diagnosis. 3. Guideline support — a letter from your prescriber citing the relevant HAE guideline organization's recommendations for prophylactic therapy. 4. Prior-treatment history — documented trials of other prophylactic agents, with dates, doses (as recorded in the chart), outcomes, and reasons for transition. 5. Prescriber medical-necessity letter — should directly counter Aetna's specific experimental-policy language point by point.

## Criteria-Mapping Structure

Request a copy of the specific Aetna clinical policy or bulletin cited in your denial letter. Copy each criterion into a table. For an experimental denial, the key criteria to address are typically: (a) whether the drug has FDA approval for the indication, (b) whether the use is on-label, and (c) whether the professional medical community has accepted this therapy as standard of care. Map each criterion to a specific piece of documentation — the FDA label, the specialist's chart notes, and the guideline organization's published position. Your prescriber's letter should mirror this structure.